GS-9620 is a potent oral agonist of toll-like receptor 7, a key modulator of the innate immune response. In healthy volunteers, low doses of GS-9620 (2, 4 and 6 mg) induced significant expression of peripheral interferon-stimulated-gene (ISG) mRNA in the absence of detectable serum interferon-α and systemic adverse events (AEs). We evaluated the safety, pharmacokinetics and pharmacodynamics of GS-9620 in treatment-naive patients chronically infected with HCV genotype 1.
Methods
In this double-blind, placebo-controlled study, 51 patients were randomized 5:1 (active:placebo) to receive either a single dose or two once-weekly doses of GS-9620 at four dose levels (0.3, 1, 2 and 4 mg) or placebo. Pharmacodynamic assessments included peripheral ISG15 mRNA expression, serum interferon-α and interferon-γ-inducible protein (IP)-10 levels and HCV RNA quantification.
Results
GS-9620 was well-tolerated at all doses. Most AEs were mild or moderate in severity. GS-9620 exhibited dose-linear pharmacokinetics with a median half-life in plasma of 18 h. Transient, dose-dependent ISG15 induction was observed at 1, 2 and 4 mg, with peak mean fold change within 48 h followed by a decline to baseline levels within 7 days of dosing. Serum interferon-α induction post-baseline was detected in 16.7% (8/48) of patients. No clinically significant reductions in HCV RNA were observed.
Conclusions
GS-9620 was safe, well-tolerated and biologically active in patients with HCV infection. Induction of ISG15 occurred in the absence of detectable serum interferon-α or systemic AEs in most patients, supporting a pre-systemic mechanism of action. ClinicalTrials.gov identifier: NCT01591668.
References
1.
ThompsonM.R., KaminskiJ.J., Kurt-JonesE.A., FitzgeraldK.A.Pattern recognition receptors and the innate immune response to viral infection.Viruses2011; 3: 920–940.
2.
BaoM., LiuY.J.Regulation of TLR7/9 signaling in plasmacytoid dendritic cells.Protein Cell2013; 4: 40–52.
3.
HeimM.H.Innate immunity and HCV.J Hepatol2013; 58: 564–574.
4.
DieboldS.S., KaishoT., HemmiH., AkiraS., Reis e SousaC.Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA.Science2004; 303: 1529–1531.
5.
LeeJ., WuC.C., LeeK.J.Activation of anti-hepatitis C virus responses via Toll-like receptor 7.Proc Natl Acad Sci U S A2006; 103: 1828–1833.
6.
KawaiT., AkiraS.Innate immune recognition of viral infection.Nat Immunol2006; 7: 131–137.
FosdickA., ZhengJ., PflanzS.Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses.J Pharmacol Exp Ther2014; 348: 96–105.
10.
LopatinU., WolfgangG., TumasD.Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist.Antivir Ther2013; 18: 409–418.
11.
FerenciP.Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future.Expert Opin Drug Saf2011; 10: 529–544.
12.
VezaliE., AghemoA., ColomboM.Interferon in the treatment of chronic hepatitis C: a drug caught between past and future.Expert Opin Biol Ther2011; 11: 301–313.
13.
LivakK.J., SchmittgenT.D.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.Methods2001; 25: 402–408.
14.
BergmannJ.F., de BruijneJ., HothoD.M.Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV.Aliment Pharmacol Ther2011; 34: 443–453.
15.
BoonstraA., LiuB.S., GroothuisminkZ.M.Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7.Antivir Ther2012; 17: 657–667.
16.
SheridanC.FDA approvals usher in the post-interferon era in HCV.Nat Biotechnol2014; 32: 3–5.
